The stock of Vertex Pharmaceuticals, Inc (VRTX) has seen a 3.63% increase in the past week, with a 11.79% gain in the past month, and a -2.52% decrease in the past quarter. The volatility ratio for the week is 2.78%, and the volatility levels for the past 30 days are at 2.70% for VRTX. The simple moving average for the past 20 days is 3.02% for VRTX’s stock, with a 1.83% simple moving average for the past 200 days.
Is It Worth Investing in Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Right Now?
The 36-month beta value for VRTX is also noteworthy at 0.42. There are mixed opinions on the stock, with 16 analysts rating it as a “buy,” 5 rating it as “overweight,” 12 rating it as “hold,” and 2 rating it as “sell.”
The public float for VRTX is 255.90M, and at present, short sellers hold a 1.78% of that float. The average trading volume of VRTX on February 20, 2025 was 1.64M shares.
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX)’s stock price has plunge by 2.09relation to previous closing price of 462.11. Nevertheless, the company has seen a 3.63% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-18 that BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Canaccord Genuity repeating the rating for VRTX by listing it as a “Hold.” The predicted price for VRTX in the upcoming period, according to Canaccord Genuity is $424 based on the research report published on February 12, 2025 of the current year 2025.
Wells Fargo gave a rating of “Equal Weight” to VRTX, setting the target price at $460 in the report published on January 30th of the current year.
VRTX Trading at 7.24% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.26% of loss for the given period.
Volatility was left at 2.70%, however, over the last 30 days, the volatility rate increased by 2.78%, as shares surge +10.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.68% upper at present.
During the last 5 trading sessions, VRTX rose by +3.63%, which changed the moving average for the period of 200-days by +17.31% in comparison to the 20-day moving average, which settled at $457.95. In addition, Vertex Pharmaceuticals, Inc saw 17.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Tatsis Ourania, who sale 244 shares at the price of $455.06 back on Feb 18 ’25. After this action, Tatsis Ourania now owns 67,695 shares of Vertex Pharmaceuticals, Inc, valued at $111,035 using the latest closing price.
Biller Jonathan, the EVP and Chief Legal Officer of Vertex Pharmaceuticals, Inc, sale 1,657 shares at $455.06 during a trade that took place back on Feb 18 ’25, which means that Biller Jonathan is holding 17,606 shares at $754,034 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.05. The total capital return value is set at -0.01. Equity return is now at value -3.15, with -2.32 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -8.07.
Currently, EBITDA for the company is 486.3 million with net debt to EBITDA at -5.8. When we switch over and look at the enterprise to sales, we see a ratio of 10.75. The receivables turnover for the company is 6.84for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.69.
Conclusion
In summary, Vertex Pharmaceuticals, Inc (VRTX) has had a better performance as of late. Analysts have bearish opinions on the stock, with some viewing it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
